Dexcom Inc

  • Earnings Score
  • Moat Score
  • Safety Score
  • Market Cap $30.61B
  • PE 45
  • Debt $2.44B
  • Cash $622.40M
  • EV $32.43B
  • FCF $535.00M

Earnings

loading chart...

Sales & Net Margins

loading chart...
Earnings$680.80M
EBIT$743.90M
ROE34%
ROA12%
FCF$535.00M
Equity$1.98B
Growth Stability99%
PE44.96
PEG1.69
PB15.47
P/FCF57.22
P/S7.74
Price/Cash0.02
Debt/Equity1.23
Debt/FCF4.56
Net Margins15%
Gross Margins62%
Op. Margins19%
Earnings CAGR10%
Sales Growth YoY2%
Sales Growth QoQ-1%
Sales CAGR31%
FCF CAGR69%
Equity CAGR38%
Earnings Stability0.16
Earnings Growth YoY12%
Earnings Growth QoQ-6%
Earnings CAGR 5Y27%
Sales CAGR 5Y23%
FCF CAGR 5Y39%
Equity CAGR 5Y15%
Earnings CAGR 3Y21%
Sales CAGR 3Y21%
FCF CAGR 3Y115%
Equity CAGR 3Y0%
Market Cap$30.61B
Revenue$3.95B
Assets$6.35B
Total Debt$2.44B
Cash$622.40M
Shares Outstanding390.6M
EV32.43B
Earnings Score9%
Moat Score95%
Safety Score84%
Final Score63%
Working Capital2.53B
Current Ratio2.46
Gross Profit$2.44B
Shares Growth 3y0%
Equity Growth QoQ-19%
Equity Growth YoY-13%

Assets & ROA

loading chart...

Stockholders Equity & ROE

loading chart...
DexCom Inc designs and commercializes continuous glucose monitoring systems for diabetics. CGM systems serve as an alternative to the traditional blood glucose meter process, and the company is evolving its CGM systems to include the disposable sensor and the durable receiver.

SEC Filings

Direct access to Dexcom Inc (DXCM) Annual Reports (10K) and Quarterly Reports (10Q) from the SEC website.

  • 2024
    • 10-Q Sep 30
    • 10-Q Jun 30
    • 10-Q Mar 31
  • 2023
    • 10-K Dec 31
    • 10-Q Sep 30
    • 10-Q Jun 30
    • 10-Q Mar 31
  • 2022
    • 10-K Dec 31
    • 10-Q Sep 30
    • 10-Q Jun 30
    • 10-Q Mar 31

Sector Comparison

How does Dexcom Inc compare to its competitors?

Loading chart...

Peter Lynch's Chart

This chart shows the current pricing of Dexcom Inc compared to its past. The addition of the earnings trend line provides further insights into the company's earnings power.

CAGR 10%
Stability 16%
loading chart...

Dexcom Inc Discounted Cash Flow

Fully customizable DCF calculator online for Dexcom Inc.

= $492B
012345678910TV
fcf$535M$902M$1.5B$2.6B$4.3B$7.3B$12B$21B$35B$59B$99B$994B
DCF$820M$1.3B$1.9B$3B$4.5B$6.9B$11B$16B$25B$38B$383B
Value$492B

Competitiveness and MOAT

High margins render the company resilient under dire circumstances, hence able to drive competitors out or acquire them. ROE and ROA measure the average flow generated by each invested dollar. Their marginal value is a forecast of future growth, and it is considered by Buffett and Munger the most important single indicator.

Years12/201412/201512/201612/201712/201812/201912/202012/202112/202212/2023TTM
Net Margins-9%-14%-11%-7%-12%7%26%6%12%15%15%
ROA--20%-16%-4%-5%7%7%5%7%11%12%
ROE--26%-23%-12%-19%11%27%7%16%26%34%

Safety and Stability

Being debt the number one cause of investment losses and company death, the ratio Debt/FCF is of utmost importance to guarantee safety. On the other hand the Graham’s stability measures the drawdown of earnings, hence indicating the reliability of the flow generated by the company.

Years12/201412/201512/201612/201712/201812/201912/202012/202112/202212/2023TTM
Debt over FCF-0012.618.017.886.0331.956.474.764.56
Debt over Equity0.03000.781.521.20.910.760.921.181.23
Growth Stability-------99%100%100%99%

Growth

Growth can be dangerous when forecasting, simply projecting the current growth is in general wrong. A company passes through multiple phases, from being young and unprofitable, to the first periods of profitability and high growth, until it arrives at a period of regime with limited growth. Identifying in which phase the company is in may help forecasting.

Years12/201412/201512/201612/201712/201812/201912/202012/202112/202212/2023CAGR 5Y
Revenue YoY growth-55%43%25%44%43%31%27%19%24%23%
Earnings YoY growth-157%14%-23%153%-180%388%-69%121%59%27%
Equity YoY growth-58%28%48%58%33%107%23%-5%-3%15%
FCF YoY growth-112%-97%5K%116%140%106%-81%472%68%39%